Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr:28:27-29.
doi: 10.1016/j.jtos.2023.01.001. Epub 2023 Jan 10.

Can Janus kinase inhibition improve ocular graft versus host disease?

Seema Sajjan  1 , Ellis Tibbs  2 , Megan Utz  1 , Aaron P Rapoport  2 , Jean Yared  2 , Saurabh Dahiya  2 , Xuefang Cao  2 , Nancy Hardy  2 , Sarah B Sunshine  3
Affiliations

Can Janus kinase inhibition improve ocular graft versus host disease?

Seema Sajjan et al. Ocul Surf. 2023 Apr.
No abstract available

Keywords: JAK inhibition; Ocular graft versus host disease; Ocular surface disease.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors report no conflict of interest.

Figures

Figure 1.
Figure 1.. Results of
A. OSDI B. Schirmers C. oGVHD D. Cumulative E. Representative slit lamp photographs of the right eye (E1–4) and left eye (E5–8). Pre-JAKi slit lamp photographs of the right eye (E1–2) and left eye (E5–6); (E1, E5) demonstrating 2+ injection and lissamine staining of the conjunctiva (E2,E6) bulbar conjunctiva with fluorescein demonstrating PEE. Post JAKi slit lamp photographs of the right eye (E3, E4) and left eye (E7,E8); (E3, E7) demonstrates improvement in lissamine staining and (E4, E8) demonstrates improvement of the PEE on the conjunctiva and cornea
See this image and copyright information in PMC

References

    1. Na K-S, Yoo Y-S, Mok JW, Lee JW & Joo C-K Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 50, 1459–1464 (2015). - PubMed
    1. Katz EA et al. Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops (“Triple Play”) in Recalcitrant Immunological Ocular Surface Diseases. Ocul Surf 23, 1–11 (2022). - PubMed
    1. Soin K, Djalilian AR & Jain S. Diagnosis and Management of Ocular Graft-Versus-Host Disease. in Ocular Surface Disease 81–91 (Springer International Publishing, 2018). doi:10.1007/978-3-319-15823-5_6. - DOI
    1. Inamoto Y. et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant 54, 662–673 (2019). - PubMed
    1. Bron AJ et al. TFOS DEWS II pathophysiology report. Ocul Surf 15, 438–510 (2017). - PubMed

Publication types